Level C· Early human research exploring benefitsProspective StudyEurope PMC

Human skeletal development and regeneration are shaped by functional diversity of stem cells across skeletal sites

Ambrosi TH., Taheri S., Chen K., Sinha R., Wang Y., Hunt EJ.

Prospective Study on Hip, published in Cell Stem Cell (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cell Stem Cell (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40118065
PMCID
PMC12048286
DOI
10.1016/j.stem.2025.02.013
Citations
10

Abstract (original English)

The skeleton is one of the most structurally and compositionally diverse organ systems in the human body, depending on unique cellular dynamisms. Here, we integrate prospective isolation of human skeletal stem cells (hSSCs; CD45 - CD235a - TIE2 - CD31 - CD146 - PDPN + CD73 + CD164 + ) from ten skeletal sites with functional assays and single-cell RNA sequencing (scRNA-seq) analysis to identify chondrogenic, osteogenic, stromal, and fibrogenic subtypes of hSSCs during development and their linkage to skeletal phenotypes. We map the distinct composition of hSSC subtypes across multiple skeletal sites and demonstrate their unique in vivo clonal dynamics. We find that age-related changes in bone formation and regeneration disorders stem from a pathological fibroblastic shift in the hSSC pool. Utilizing a Boolean algorithm, we uncover gene regulatory networks that dictate differences in the ability of hSSCs to generate specific skeletal tissues. Importantly, hSSC lineage dynamics are pharmacologically malleable, providing a new strategy to treat aberrant hSSC diversity central to aging and skeletal maladies.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Bone and BonesStem CellsHumansRegenerationBone RegenerationCell DifferentiationBone DevelopmentOsteogenesisAdultMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research